Evolution  ||| S:0 E:10 ||| NN
in  ||| S:10 E:13 ||| IN
the  ||| S:13 E:17 ||| DT
antibiotic  ||| S:17 E:28 ||| JJ
susceptibility  ||| S:28 E:43 ||| NN
and  ||| S:43 E:47 ||| CC
resistance  ||| S:47 E:58 ||| NN
Over  ||| S:58 E:63 ||| IN
the  ||| S:63 E:67 ||| DT
last  ||| S:67 E:72 ||| JJ
decade  ||| S:72 E:79 ||| NN
the  ||| S:79 E:83 ||| DT
proliferation  ||| S:83 E:97 ||| NN
of  ||| S:97 E:100 ||| IN
antibiotic-resistant  ||| S:100 E:121 ||| JJ
pathogens  ||| S:121 E:131 ||| NN
has  ||| S:131 E:135 ||| VBZ
been  ||| S:135 E:140 ||| VBN
a  ||| S:140 E:142 ||| DT
growing  ||| S:142 E:150 ||| VBG
problem ||| S:150 E:157 ||| NN
,  ||| S:157 E:159 ||| ,
especially  ||| S:159 E:170 ||| RB
in  ||| S:170 E:173 ||| IN
some  ||| S:173 E:178 ||| DT
geographic  ||| S:178 E:189 ||| JJ
areas ||| S:189 E:194 ||| NNS
,  ||| S:194 E:196 ||| ,
making  ||| S:196 E:203 ||| VBG
useless  ||| S:203 E:211 ||| JJ
most  ||| S:211 E:216 ||| JJS
of  ||| S:216 E:219 ||| IN
the  ||| S:219 E:223 ||| DT
classical  ||| S:223 E:233 ||| JJ
antibiotic  ||| S:233 E:244 ||| JJ
therapies ||| S:244 E:253 ||| NNS
.  ||| S:253 E:255 ||| .
The  ||| S:255 E:259 ||| DT
rapid  ||| S:259 E:265 ||| JJ
emergence  ||| S:265 E:275 ||| NN
of  ||| S:275 E:278 ||| IN
resistant  ||| S:278 E:288 ||| JJ
bacteria  ||| S:288 E:297 ||| NNS
is  ||| S:297 E:300 ||| VBZ
the  ||| S:300 E:304 ||| DT
result  ||| S:304 E:311 ||| NN
of  ||| S:311 E:314 ||| IN
different  ||| S:314 E:324 ||| JJ
factors  ||| S:324 E:332 ||| NNS
as  ||| S:332 E:335 ||| IN
the  ||| S:335 E:339 ||| DT
intrinsic  ||| S:339 E:349 ||| JJ
microbial  ||| S:349 E:359 ||| JJ
complexity ||| S:359 E:369 ||| NN
,  ||| S:369 E:371 ||| ,
the  ||| S:371 E:375 ||| DT
growing  ||| S:375 E:383 ||| VBG
attitude  ||| S:383 E:392 ||| NN
to  ||| S:392 E:395 ||| TO
travel  ||| S:395 E:402 ||| VB
of  ||| S:402 E:405 ||| IN
humans ||| S:405 E:411 ||| NNS
,  ||| S:411 E:413 ||| ,
animals  ||| S:413 E:421 ||| NNS
and  ||| S:421 E:425 ||| CC
goods ||| S:425 E:430 ||| NNS
,  ||| S:430 E:432 ||| ,
the  ||| S:432 E:436 ||| DT
use  ||| S:436 E:440 ||| NN
of  ||| S:440 E:443 ||| IN
antibiotics  ||| S:443 E:455 ||| JJ
outside  ||| S:455 E:463 ||| JJ
hospitals ||| S:463 E:472 ||| NNS
,  ||| S:472 E:474 ||| ,
and  ||| S:474 E:478 ||| CC
the  ||| S:478 E:482 ||| DT
lack  ||| S:482 E:487 ||| NN
of  ||| S:487 E:490 ||| IN
precise  ||| S:490 E:498 ||| JJ
therapeutic  ||| S:498 E:510 ||| NN
chooses  ||| S:510 E:518 ||| VBZ
for  ||| S:518 E:522 ||| IN
high  ||| S:522 E:527 ||| JJ
risk  ||| S:527 E:532 ||| NN
group  ||| S:532 E:538 ||| NN
of  ||| S:538 E:541 ||| IN
patients ||| S:541 E:549 ||| NNS
.  ||| S:549 E:551 ||| .
The  ||| S:551 E:555 ||| DT
antibiotic-resistance  ||| S:555 E:577 ||| NN
becomes  ||| S:577 E:585 ||| VBZ
certainly  ||| S:585 E:595 ||| RB
a  ||| S:595 E:597 ||| DT
serious  ||| S:597 E:605 ||| JJ
problem  ||| S:605 E:613 ||| NN
when  ||| S:613 E:618 ||| WRB
a  ||| S:618 E:620 ||| DT
resistant  ||| S:620 E:630 ||| JJ
pathogen ||| S:630 E:638 ||| NN
,  ||| S:638 E:640 ||| ,
and  ||| S:640 E:644 ||| CC
often  ||| S:644 E:650 ||| RB
multi-resistant  ||| S:650 E:666 ||| JJ
today ||| S:666 E:671 ||| NN
,  ||| S:671 E:673 ||| ,
is  ||| S:673 E:676 ||| VBZ
present  ||| S:676 E:684 ||| JJ
in  ||| S:684 E:687 ||| IN
an  ||| S:687 E:690 ||| DT
infective  ||| S:690 E:700 ||| JJ
site ||| S:700 E:704 ||| NN
.  ||| S:704 E:706 ||| .
In  ||| S:706 E:709 ||| IN
fact  ||| S:709 E:714 ||| NN
in  ||| S:714 E:717 ||| IN
a  ||| S:717 E:719 ||| DT
recent  ||| S:719 E:726 ||| JJ
estimate  ||| S:726 E:735 ||| NN
of  ||| S:735 E:738 ||| IN
the  ||| S:738 E:742 ||| DT
Centre  ||| S:742 E:749 ||| NNP
for  ||| S:749 E:753 ||| IN
Disease  ||| S:753 E:761 ||| NNP
Control  ||| S:761 E:769 ||| NNP
and  ||| S:769 E:773 ||| CC
Prevention  ||| S:773 E:784 ||| NNP
( ||| S:784 E:785 ||| -LRB-
CDC ||| S:785 E:788 ||| NNP
)  ||| S:788 E:790 ||| -RRB-
about  ||| S:790 E:796 ||| IN
90.000  ||| S:796 E:803 ||| CD
deaths  ||| S:803 E:810 ||| NNS
per  ||| S:810 E:814 ||| IN
year  ||| S:814 E:819 ||| NN
in  ||| S:819 E:822 ||| IN
the  ||| S:822 E:826 ||| DT
USA  ||| S:826 E:830 ||| NNP
are  ||| S:830 E:834 ||| VBP
attributable  ||| S:834 E:847 ||| JJ
to  ||| S:847 E:850 ||| TO
bacterial  ||| S:850 E:860 ||| JJ
infections  ||| S:860 E:871 ||| NNS
and  ||| S:871 E:875 ||| CC
in  ||| S:875 E:878 ||| IN
particular  ||| S:878 E:889 ||| JJ
to  ||| S:889 E:892 ||| TO
resistant  ||| S:892 E:902 ||| JJ
pathogens ||| S:902 E:911 ||| NN
.  ||| S:911 E:913 ||| .
It  ||| S:913 E:916 ||| PRP
appears  ||| S:916 E:924 ||| VBZ
clear  ||| S:924 E:930 ||| JJ
that  ||| S:930 E:935 ||| IN
the  ||| S:935 E:939 ||| DT
clinic  ||| S:939 E:946 ||| NN
relevance  ||| S:946 E:956 ||| NN
of  ||| S:956 E:959 ||| IN
this  ||| S:959 E:964 ||| DT
problem  ||| S:964 E:972 ||| NN
is  ||| S:972 E:975 ||| VBZ
the  ||| S:975 E:979 ||| DT
decimation  ||| S:979 E:990 ||| NN
of  ||| S:990 E:993 ||| IN
the  ||| S:993 E:997 ||| DT
sensible  ||| S:997 E:1006 ||| JJ
germs  ||| S:1006 E:1012 ||| NNS
of  ||| S:1012 E:1015 ||| IN
the  ||| S:1015 E:1019 ||| DT
normal  ||| S:1019 E:1026 ||| JJ
flora  ||| S:1026 E:1032 ||| NNS
that  ||| S:1032 E:1037 ||| WDT
leads  ||| S:1037 E:1043 ||| VBZ
to  ||| S:1043 E:1046 ||| TO
the  ||| S:1046 E:1050 ||| DT
upper  ||| S:1050 E:1056 ||| JJ
hand  ||| S:1056 E:1061 ||| NN
of  ||| S:1061 E:1064 ||| IN
the  ||| S:1064 E:1068 ||| DT
only  ||| S:1068 E:1073 ||| JJ
resistant  ||| S:1073 E:1083 ||| JJ
bacteria ||| S:1083 E:1091 ||| NNS
.  ||| S:1091 E:1093 ||| .
The  ||| S:1093 E:1097 ||| DT
antibiotic  ||| S:1097 E:1108 ||| JJ
therapy ||| S:1108 E:1115 ||| NN
,  ||| S:1115 E:1117 ||| ,
in  ||| S:1117 E:1120 ||| IN
fact ||| S:1120 E:1124 ||| NN
,  ||| S:1124 E:1126 ||| ,
select  ||| S:1126 E:1133 ||| VB
the  ||| S:1133 E:1137 ||| DT
resistance  ||| S:1137 E:1148 ||| NN
and  ||| S:1148 E:1152 ||| CC
each  ||| S:1152 E:1157 ||| DT
bacteria  ||| S:1157 E:1166 ||| NN
has  ||| S:1166 E:1170 ||| VBZ
developed  ||| S:1170 E:1180 ||| VBN
a  ||| S:1180 E:1182 ||| DT
particular  ||| S:1182 E:1193 ||| JJ
strategy  ||| S:1193 E:1202 ||| NN
to  ||| S:1202 E:1205 ||| TO
survive ||| S:1205 E:1212 ||| VB
:  ||| S:1212 E:1214 ||| :
mutations  ||| S:1214 E:1224 ||| NNS
of  ||| S:1224 E:1227 ||| IN
the  ||| S:1227 E:1231 ||| DT
genetic  ||| S:1231 E:1239 ||| JJ
content  ||| S:1239 E:1247 ||| NN
or  ||| S:1247 E:1250 ||| CC
acquisition  ||| S:1250 E:1262 ||| NN
of  ||| S:1262 E:1265 ||| IN
resistance  ||| S:1265 E:1276 ||| NN
genes  ||| S:1276 E:1282 ||| NNS
from  ||| S:1282 E:1287 ||| IN
the  ||| S:1287 E:1291 ||| DT
external ||| S:1291 E:1299 ||| JJ
.  ||| S:1299 E:1301 ||| .
Among  ||| S:1301 E:1307 ||| IN
the  ||| S:1307 E:1311 ||| DT
Gram  ||| S:1311 E:1316 ||| JJ
positive  ||| S:1316 E:1325 ||| JJ
bacteria ||| S:1325 E:1333 ||| NNS
,  ||| S:1333 E:1335 ||| ,
besides  ||| S:1335 E:1343 ||| FW
methicillin  ||| S:1343 E:1355 ||| FW
resistant  ||| S:1355 E:1365 ||| FW
Staphyloccocus  ||| S:1365 E:1380 ||| FW
aureus ||| S:1380 E:1386 ||| FW
,  ||| S:1386 E:1388 ||| ,
there  ||| S:1388 E:1394 ||| EX
are  ||| S:1394 E:1398 ||| VBP
other  ||| S:1398 E:1404 ||| JJ
pathogens  ||| S:1404 E:1414 ||| JJ
such  ||| S:1414 E:1419 ||| JJ
as  ||| S:1419 E:1422 ||| IN
coagulase-negative  ||| S:1422 E:1441 ||| JJ
staphylococci  ||| S:1441 E:1455 ||| NNS
( ||| S:1455 E:1456 ||| -LRB-
CoNS ||| S:1456 E:1460 ||| NNP
) ||| S:1460 E:1461 ||| -RRB-
,  ||| S:1461 E:1463 ||| ,
Enterococcus  ||| S:1463 E:1476 ||| NNP
faecium  ||| S:1476 E:1484 ||| NN
and  ||| S:1484 E:1488 ||| CC
Enterococcus  ||| S:1488 E:1501 ||| NNP
faecalis ||| S:1501 E:1509 ||| NN
,  ||| S:1509 E:1511 ||| ,
some  ||| S:1511 E:1516 ||| DT
species  ||| S:1516 E:1524 ||| NN
of  ||| S:1524 E:1527 ||| IN
streptococci  ||| S:1527 E:1540 ||| NN
and  ||| S:1540 E:1544 ||| CC
multiresistant  ||| S:1544 E:1559 ||| JJ
Corynebacterium ||| S:1559 E:1574 ||| NNP
.  ||| S:1574 E:1576 ||| .
The  ||| S:1576 E:1580 ||| DT
CoNS ||| S:1580 E:1584 ||| JJ
,  ||| S:1584 E:1586 ||| ,
eg ||| S:1586 E:1588 ||| NN
.  ||| S:1588 E:1590 ||| .
S.  ||| S:1590 E:1593 ||| NNP
epidermidis ||| S:1593 E:1604 ||| NN
,  ||| S:1604 E:1606 ||| ,
S.  ||| S:1606 E:1609 ||| NNP
hominis  ||| S:1609 E:1617 ||| NN
and  ||| S:1617 E:1621 ||| CC
S.  ||| S:1621 E:1624 ||| NNP
haemolyticus ||| S:1624 E:1636 ||| NN
,  ||| S:1636 E:1638 ||| ,
are  ||| S:1638 E:1642 ||| VBP
recognized  ||| S:1642 E:1653 ||| VBN
as  ||| S:1653 E:1656 ||| IN
new  ||| S:1656 E:1660 ||| JJ
important  ||| S:1660 E:1670 ||| JJ
nosocomial  ||| S:1670 E:1681 ||| JJ
pathogens  ||| S:1681 E:1691 ||| NN
and  ||| S:1691 E:1695 ||| CC
are  ||| S:1695 E:1699 ||| VBP
not  ||| S:1699 E:1703 ||| RB
only  ||| S:1703 E:1708 ||| RB
responsible  ||| S:1708 E:1720 ||| JJ
of  ||| S:1720 E:1723 ||| IN
invasive  ||| S:1723 E:1732 ||| JJ
infections  ||| S:1732 E:1743 ||| NNS
but  ||| S:1743 E:1747 ||| CC
have  ||| S:1747 E:1752 ||| VBP
become  ||| S:1752 E:1759 ||| VBN
in  ||| S:1759 E:1762 ||| IN
few  ||| S:1762 E:1766 ||| JJ
years  ||| S:1766 E:1772 ||| NNS
resistant  ||| S:1772 E:1782 ||| VBP
to  ||| S:1782 E:1785 ||| TO
oxacillin  ||| S:1785 E:1795 ||| VB
( ||| S:1795 E:1796 ||| -LRB-
more  ||| S:1796 E:1801 ||| JJR
than  ||| S:1801 E:1806 ||| IN
60 ||| S:1806 E:1808 ||| CD
% ||| S:1808 E:1809 ||| NN
)  ||| S:1809 E:1811 ||| -RRB-
and  ||| S:1811 E:1815 ||| CC
multiresistant ||| S:1815 E:1829 ||| NN
.  ||| S:1829 E:1831 ||| .
The  ||| S:1831 E:1835 ||| DT
unsuspected  ||| S:1835 E:1847 ||| JJ
fragility  ||| S:1847 E:1857 ||| NN
of  ||| S:1857 E:1860 ||| IN
glycopeptides ||| S:1860 E:1873 ||| NN
,  ||| S:1873 E:1875 ||| ,
which  ||| S:1875 E:1881 ||| WDT
for  ||| S:1881 E:1885 ||| IN
40  ||| S:1885 E:1888 ||| CD
years  ||| S:1888 E:1894 ||| NNS
have  ||| S:1894 E:1899 ||| VBP
been  ||| S:1899 E:1904 ||| VBN
the  ||| S:1904 E:1908 ||| DT
most  ||| S:1908 E:1913 ||| RBS
important  ||| S:1913 E:1923 ||| JJ
treatment  ||| S:1923 E:1933 ||| NN
against  ||| S:1933 E:1941 ||| IN
infections  ||| S:1941 E:1952 ||| JJ
due  ||| S:1952 E:1956 ||| JJ
to  ||| S:1956 E:1959 ||| TO
Gram-positive  ||| S:1959 E:1973 ||| JJ
bacteria ||| S:1973 E:1981 ||| NNS
,  ||| S:1981 E:1983 ||| ,
has  ||| S:1983 E:1987 ||| VBZ
posed  ||| S:1987 E:1993 ||| VBN
the  ||| S:1993 E:1997 ||| DT
need  ||| S:1997 E:2002 ||| NN
for  ||| S:2002 E:2006 ||| IN
new  ||| S:2006 E:2010 ||| JJ
antimicrobial  ||| S:2010 E:2024 ||| JJ
molecules ||| S:2024 E:2033 ||| NNS
.  ||| S:2033 E:2035 ||| .
Among  ||| S:2035 E:2041 ||| IN
the  ||| S:2041 E:2045 ||| DT
therapeutic  ||| S:2045 E:2057 ||| JJ
possible  ||| S:2057 E:2066 ||| JJ
options  ||| S:2066 E:2074 ||| NNS
there  ||| S:2074 E:2080 ||| EX
are  ||| S:2080 E:2084 ||| VBP
linezolid ||| S:2084 E:2093 ||| VBN
,  ||| S:2093 E:2095 ||| ,
tygecyline  ||| S:2095 E:2106 ||| NN
and  ||| S:2106 E:2110 ||| CC
daptomycin ||| S:2110 E:2120 ||| NN
,  ||| S:2120 E:2122 ||| ,
but  ||| S:2122 E:2126 ||| CC
new  ||| S:2126 E:2130 ||| JJ
other  ||| S:2130 E:2136 ||| JJ
molecules  ||| S:2136 E:2146 ||| NNS
are  ||| S:2146 E:2150 ||| VBP
appearing  ||| S:2150 E:2160 ||| VBG
in  ||| S:2160 E:2163 ||| IN
the  ||| S:2163 E:2167 ||| DT
clinical  ||| S:2167 E:2176 ||| JJ
use  ||| S:2176 E:2180 ||| NN
like  ||| S:2180 E:2185 ||| IN
ceftobiprole  ||| S:2185 E:2198 ||| NN
and  ||| S:2198 E:2202 ||| CC
dalbavancin ||| S:2202 E:2213 ||| NN
.  ||| S:2213 E:2215 ||| .
